Biocon 향후 성장

Future 기준 점검 4/6

Biocon (는) 각각 연간 55.5% 및 14.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 51.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 6.3% 로 예상됩니다.

핵심 정보

55.5%

이익 성장률

51.63%

EPS 성장률

Biotechs 이익 성장	40.7%
매출 성장률	14.5%
향후 자기자본이익률	6.26%
애널리스트 커버리지	Good
마지막 업데이트	06 Jan 2026

최근 향후 성장 업데이트

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 10

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Jun 19

Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Feb 02

Recent updates

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Sep 22

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 10

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Aug 04

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Jun 19

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

Jun 18

Biocon (NSE:BIOCON) Has Affirmed Its Dividend Of ₹0.50

May 12

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Apr 18

Biocon Limited's (NSE:BIOCON) Business Is Trailing The Market But Its Shares Aren't

Mar 10

Does Biocon (NSE:BIOCON) Have A Healthy Balance Sheet?

Feb 20

Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Feb 02

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Jan 19

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Dec 12 Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

이익 및 매출 성장 예측

NSEI:BIOCON - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2028	234,151	19,291	32,377	41,745	13
3/31/2027	206,202	13,834	26,362	35,818	17
3/31/2026	175,390	6,016	19,132	28,928	17
9/30/2025	164,758	4,855	17,973	41,592	N/A
6/30/2025	157,707	3,850	N/A	N/A	N/A
3/31/2025	152,617	10,133	17,179	40,612	N/A
12/31/2024	147,618	8,043	N/A	N/A	N/A
9/30/2024	148,941	14,392	21,045	40,368	N/A
6/30/2024	147,660	15,808	N/A	N/A	N/A
3/31/2024	147,557	10,225	10,223	29,539	N/A
12/31/2023	146,125	12,002	N/A	N/A	N/A
9/30/2023	135,999	4,984	-6,241	11,717	N/A
6/30/2023	124,573	4,197	N/A	N/A	N/A
3/31/2023	111,742	4,627	1,262	18,525	N/A
12/31/2022	98,091	3,881	N/A	N/A	N/A
9/30/2022	90,422	6,170	-6,836	11,543	N/A
6/30/2022	85,629	7,084	N/A	N/A	N/A
3/31/2022	81,840	6,484	-7,482	11,766	N/A
12/31/2021	75,800	6,727	N/A	N/A	N/A
9/30/2021	72,632	6,542	-6,366	12,763	N/A
6/30/2021	71,726	6,852	N/A	N/A	N/A
3/31/2021	71,431	7,405	-5,866	11,597	N/A
12/31/2020	68,913	5,996	N/A	N/A	N/A
9/30/2020	67,571	6,362	-6,576	10,484	N/A
6/30/2020	65,796	6,870	N/A	N/A	N/A
3/31/2020	63,005	7,771	-5,534	12,831	N/A
12/31/2019	63,150	8,385	N/A	N/A	N/A
9/30/2019	61,077	8,529	-3,416	14,573	N/A
6/30/2019	58,565	9,919	N/A	N/A	N/A
3/31/2019	55,144	9,053	N/A	11,546	N/A
12/31/2018	51,551	8,220	N/A	N/A	N/A
9/30/2018	46,722	6,967	N/A	N/A	N/A
6/30/2018	43,198	4,108	N/A	N/A	N/A
3/31/2018	41,234	3,724	N/A	6,621	N/A
12/31/2017	38,792	3,695	N/A	N/A	N/A
9/30/2017	38,589	4,489	N/A	N/A	N/A
6/30/2017	38,361	5,268	N/A	N/A	N/A
3/31/2017	38,911	6,121	N/A	6,400	N/A
12/31/2016	40,487	11,633	N/A	N/A	N/A
9/30/2016	38,110	10,961	N/A	N/A	N/A
6/30/2016	36,539	9,388	N/A	N/A	N/A
3/31/2016	33,474	5,504	N/A	3,706	N/A
12/31/2015	32,997	7,367	N/A	N/A	N/A
9/30/2015	32,325	7,247	N/A	N/A	N/A
6/30/2015	31,528	5,207	N/A	N/A	N/A
3/31/2015	30,898	4,974	N/A	2,107	N/A

애널리스트 향후 성장 전망

수입 대 저축률: BIOCON 의 연간 예상 수익 증가율(55.5%)이 saving rate(6.8%)보다 높습니다.

수익 vs 시장: BIOCON 의 연간 수익(55.5%)이 Indian 시장(16.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: BIOCON 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: BIOCON 의 수익(연간 14.5%)이 Indian 시장(연간 10.9%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: BIOCON 의 수익(연간 14.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: BIOCON의 자본 수익률은 3년 후 6.3%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/07 09:10
종가	2026/01/07 00:00
수익	2025/09/30
연간 수익	2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Biocon Limited는 42명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Meeta Shetty	Asian Markets Securities Private Limited
Harith Ahamed	Avendus Spark
Vijayaraghavan Swaminathan	Avendus Spark

Biocon 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 8.8% to ₹413

Consensus EPS estimates fall by 23%

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Price target increased by 7.4% to ₹376

Recent updates

Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

Price target increased by 8.8% to ₹413

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Biocon Biologics' Yesafili (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases

Consensus EPS estimates fall by 23%

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Biocon Limited to Report Q3, 2026 Results on Feb 12, 2026

Biocon Limited to Report Q1, 2026 Results on Aug 07, 2025

Upcoming dividend of ₹0.50 per share

Biocon Limited has completed a Follow-on Equity Offering in the amount of INR 45 billion.

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

Biocon Limited has filed a Follow-on Equity Offering.

Biocon (NSE:BIOCON) Has Affirmed Its Dividend Of ₹0.50

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Dividend of ₹0.50 announced

Biocon Limited, Annual General Meeting, Aug 08, 2025

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited to Report Q4, 2025 Results on May 08, 2025

Biocon Limited's (NSE:BIOCON) Business Is Trailing The Market But Its Shares Aren't

Biocon Biologics and Biocon Ltd. Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

Does Biocon (NSE:BIOCON) Have A Healthy Balance Sheet?

Equillium and Biocon Limited Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Now 20% overvalued after recent price rise

Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

New minor risk - Profit margin trend

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Resignation of Mayank Verma as Company Secretary & Compliance Officer, with Effect from Close of Business Hours on April 14, 2025

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Price target increased by 7.4% to ₹376

Price target increased by 8.2% to ₹371

Biocon Limited to Report Q3, 2025 Results on Jan 30, 2025

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

U.S. FDA Approves Biocon Biologics' YESINTEK, Bmab 1200 Biosimilar to J&J's Stelara (Ustekinumab)

Consensus EPS estimates fall by 20%

New major risk - Financial position

Second quarter 2025 earnings released: ₹0.13 loss per share (vs ₹1.05 profit in 2Q 2024)

Biocon Limited to Report Q2, 2025 Results on Oct 30, 2024

High number of new directors

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024

Upcoming dividend of ₹0.50 per share

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Investor sentiment improves as stock rises 18%

New minor risk - Earnings quality

Dividend of ₹0.50 announced

Biocon Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹5.3m worth of stock

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer